Clinical Trials Browser

Taxes × Breast × Clear all

NCT04090398 2026-03-19

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2 Active not recruiting

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04143711 2026-03-18

Study of DF1001 in Patients With Advanced Solid Tumors

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05422794 2026-03-18

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase 3 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT03725436 2026-03-16

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04001829 2026-03-13

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Phase 2 Active not recruiting

249 enrolled 14 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT04266249 2026-03-02

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT07340398 2026-01-21

TAYLOR

Phase 2 Recruiting

HER2-positive Early Breast Cancer

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT02654119 2025-12-12

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Phase 2 Completed

Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02593175 2025-11-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

Phase 2 Completed

43 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04329065 2025-11-06

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Phase 2 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT05929768 2025-11-05

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Phase 3 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02876107 2025-10-10

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01463072 2025-07-28

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

40 enrolled 17 charts

Breast Neoplasms

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Phase 3 Completed

3,270 enrolled 16 charts

Breast Neoplasms

NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Phase 1 Completed

11 enrolled 9 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT00609791 2025-06-19

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Phase 2 Active not recruiting

40 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT03535701 2025-06-08

KETO-CARE

Phase 1 Completed

Stage IV Breast Cancer AJCC v6 and v7

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

9 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT06632405 2025-03-26

A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT01525966 2025-03-03

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06786026 2025-02-06

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast Neoplasms

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT02689427 2024-09-19

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase 3 Suspended

201 enrolled 19 charts

Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1 Completed

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis